about
Cytokine-mediated blood brain barrier disruption as a conduit for cancer/chemotherapy-associated neurotoxicity and cognitive dysfunction.Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity.ErbB small molecule tyrosine kinase inhibitor (TKI) induced diarrhoea: Chloride secretion as a mechanistic hypothesis.Management of Mucositis During Chemotherapy: From Pathophysiology to Pragmatic Therapeutics.A novel in vitro platform for the study of SN38-induced mucosal damage and the development of Toll-like receptor 4-targeted therapeutic options.Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are Mediated by Common TLR4-Dependent Mechanisms.Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report.TLR4-Dependent Claudin-1 Internalization and Secretagogue-Mediated Chloride Secretion Regulate Irinotecan-Induced Diarrhea.Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.Routine assessment of the gut microbiome to promote preclinical research reproducibility and transparency.Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer.Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis.Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.Editorial CommentSelective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat ModelSystematic review of agents for the management of cancer treatment-related gastrointestinal mucositis and clinical practice guidelinesGut microbiota: implications for radiotherapy response and radiotherapy-induced mucositisHighlight article: Use of zebrafish to model chemotherapy and targeted therapy gastrointestinal toxicity
P50
Q30390049-23446A20-B882-44CF-9037-0786156F2C91Q38289865-741A2A29-048E-4378-9644-E568FFAFC9F8Q38527526-7E49071E-F590-4FAD-B484-89159D41E8A1Q38589005-1FC8B1A1-DC88-4A64-B745-B9CDF428CC67Q38781452-B3002E22-03F0-485F-AF63-BA95DC27B9E2Q39752593-CEADD216-F44B-4A08-83B6-01183AD09548Q47786578-DBC50F54-FADD-4F47-B1B8-946B16A467F1Q47909399-94C30495-0DE1-4AF2-ABAC-8F62AE294B34Q47958065-39CD0F79-1835-4CA8-AC77-CE2536C4AFABQ48108194-8B854CD5-70F1-49AE-9B5F-465E1D68EC4DQ48370401-B1467694-CE1E-4B92-B3BC-AF67CF37BECAQ52664243-557963D8-1AE9-4407-9D40-7B02614E469BQ54982076-64EE9296-091C-436E-A959-03DE7910D016Q55025997-F71E8DE6-9239-4AEA-85AC-13767AB4D9EFQ61459758-9E18ABBE-5EC7-419D-9466-E6A2A4EBDEB7Q64272625-94FF8889-F6FB-4CE2-AFE4-DA24125CB2B0Q91728608-1DEC27B1-2CAD-48FB-BD10-7EDCA304405CQ92589819-E1103C5F-7BFC-424A-9E86-E35E5C86213DQ92656556-87E1AAB0-9D18-4CE5-A58D-FFB100314D09
P50
description
investigador
@es
researcher
@en
name
Ysabella Z A Van Sebille
@en
type
label
Ysabella Z A Van Sebille
@en
prefLabel
Ysabella Z A Van Sebille
@en
P31
P496
0000-0002-5803-3230